An observational study in Ulcerative Colitis (UC) and Crohns Disease, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 2 sites in India. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Asian Institute of Gastroenterology, India · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Colitis, Ulcerative with a site in India — 10 open to participants now, 20 under way, 8 of them phase 3. Colitis, Ulcerative · India.
Among the 58 studies in Colitis, Ulcerative with a site in India, this one is one of 4 that started in 2026, is one of 2 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 55th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →10 of the 58 studies in Colitis, Ulcerative with a site in India are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in India, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in India, United States, Argentina and 25 more countries
Ages 18–80
Eli Lilly and Company · Sites in India, United States, Austria and 14 more countries
Ages 18–80
Genentech, Inc. · Sites in India, United States, Australia and 12 more countries
Ages 18+
Spyre Therapeutics, Inc. · Sites in India, United States, Argentina and 33 more countries
Ages 18–75
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 21 · Phase 3 29 · Phase 4 4
First in 2005; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 341 across the 56 interventional studies, 150 across the 2 observational. Of the 33 that completed or were terminated, 26 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 58 have an industry lead sponsor. The 10 most frequent:
Asian Institute of Gastroenterology, India is the lead sponsor of 135 studies on the registry; 59 are open to participants now.
Asian Institute of Gastroenterology, India has 7 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
8 of the studies in Colitis, Ulcerative with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT07431983Asian Institute of Gastroenterology, IndiaProspective Evaluation of the Carbon Footprint and Clinical Utility of IBUS Compared to Colonoscopy and Enterography in UC and CD | 2026-12 |
| NCT06895252All India Institute of Medical Sciences, New DelhiA Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Newly Diagnosed Active Ulcerative Colitis | 2027-03-15 |
| NCT06906445All India Institute of Medical Sciences, New DelhiA Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Ulcerative Colitis on Advanced Therapies | 2027-03-15 |
| NCT07186101Eli Lilly and CompanyLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | 2027-05 |
Add all 8 to your calendar (.ics) → With an account.
Among the 58 studies in Colitis, Ulcerative with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD.
Healthcare contributes approximately 4.4% of global GHG emissions, with diagnostic imaging and endoscopic services being substantial contributors. Colonoscopy and cross-sectional imaging modalities, though indispensable, are associated with high carbon emissions due to electricity use, waste, sterilisation, and transportation. IBUS, a non-invasive, real-time diagnostic modality, is increasingly validated for disease activity assessment in both UC and CD. Its low energy footprint and portability make it a potential frontline tool for sustainable IBD follow-up. This study aims to quantify and compare the environmental impact and diagnostic value of IBUS versus conventional imaging strategies in real-world clinical care.
Duration: 12 months
Sample Size:
100 UC patients (Colonoscopy + IBUS), 100 CD patients (CT/MRI enterography + IBUS), Total: 200 Patients
All consecutive patients undergoing endoscopy procedures with consent for procedures, during the study period will be included
carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging colonoscopy in patients with Ulcerative Colitis Colonoscopy+ IBUS
carbon footprint and clinical usefulness of Intestinal Bowel Ultrasound (IBUS) with standard imaging CT/MRI enterography in patients with Crohn's Disease CT/MRI enterography+ IBUS
The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed
The waste generated will be stratified according to the methods of disposal as Direct landfill, Incineration, and landfill or Recyclable waste. The electricity consumed, water consumed, waste generated, and Greenhouse Gas (GHG) emissions will be analyzed. The unit of emissions will remain same kgCO2e and the total emissions will then be calculated.
Time frame: 12 months
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 9 months is below that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Asian Institute of Gastroenterology, India →